Evaluation of eslicarbazepine for its antidiuretic effect in albino wistar rats
Keywords:Eslicarbazepine, Antidiuretic, Diabetes insipidus
Background: Diabetes insipidus is characterized by polyuria, polydipsia with hyposthenuria, causing dehydration and hypernatremia if the patient is deprived of water. Vasopressin analogues and drugs causing water retention are used in this condition. The aim of the present study was to evaluate the antidiuretic effect of eslicarbazepine in albino rats.
Methods: The animals were divided into 3 groups each containing 6 animals. The first group was constituted by the control group which received distilled water. The second was the standard group which received vasopressin. The third group was constituted by the test group which received the test drug eslicarbazepine. The test drug was given for a period of 5 days. On 5th day, one hour after administration of respective drugs in different groups, diuresis was induced in all groups of animals by Furosemide after they were loaded with normal saline after overnight fasting. The volume of urine collected was measured at the end of 5 hours from each of the group along with sodium, potassium and chloride concentrations.
Results: There was significant water retention and urine was concentrated in the test group which received eslicarbazepine when compared to the control group.
Conclusions: Eslicarbazepine has significant water retaining capacity in albino wistar rats. Further evaluation is required before using it in diabetes insipidus.
Nicolaidis S. Physiology of thirst. In: Arnaud MJ, editor. Hydration Throughout Life. Montrouge: John Libbey Eurotext; 1998: 247.
Rang HP, Ritter JM, Flower RJ. Drugs affecting major organ systems, the pituitary and the adrenal cortex. In: Rang and Dale’s pharmacology, 6th edition. Elsevier; 2008: 425-426.
Verbalis JG. Diabetes insipidus. Rev Endocr Metab Disord. 2003;4(2):177-85.
Dong X, Leppik IK, White J, Rarick J. Hyponatremia associated with oxcarbazepine and sodium valproate. Neurology. 2005;65(12):1976-8.
Rogawski MA. Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res. 2006;69(3):273-94.
Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience. 2004;5(7):553–64.
Satish AM, Sibgatullah Md, Pushpa VH, Kalabharathi HL, Kishore MS, Vaibhavi PS. Evaluation of antidiuretic effect of escitalopram in albino wistar rats. World journal of pharmacy and pharmaceutical sciences. 2014;3(12):1781-4.
Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007;48(3):497-504.
Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2-3):278-85.
Bickler RN. Treatment of diabetes insipidus with carbamazepine. Lancet. 1976;2:749-52.